DOCSLIB.ORG

Datasheet for Α2,3,6,8,9 Neuraminidase A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Datasheet for Α2,3,6,8,9 Neuraminidase A Detailed Specificity: Source: Cloned from Arthrobacter ureafaciens and Molecular Weight: 100,000 daltons. α2-3,6,8,9 α2-3,6,8,9 Neuraminidase A will cleave branched expressed in E. coli (2). sialic acid residues that are linked to an internal resi- Quality Assurance: No contaminating Neuraminidase A due. This oligosaccharide from fetuin is an example Supplied in: 50 mM NaCl, 20 mM Tris-HCl (pH 7.5 @ exoglycosidase or endoglycosidase F1, F2 or of a side-branch sialic acid residue that can efficiently 25°C) and 1 mM EDTA. F3 activity could be detected. No contaminating 1-800-632-7799 be cleaved (1). proteolytic activity could be detected. [email protected] Reagents Supplied with Enzyme: www.neb.com 10X GlycoBuffer 1 α(2–3,6) β(1–4) β(1–2) Quality Controls P0722S 001150217021 (0.5 M Sodium Acetate, pH 5.5 @ 25°C and α Glycosidase Assays: 100 units of α2-3,6,8,9 (1–6) 50 mM CaCl ) 2 Neuraminidase A were incubated with 0.1 mM P0722S 2–3,6) β(1–4) β(1–4) of flourescently-labeled oligosaccharides and α( Unit Definition: One unit is defined as the amount 800 units 20,000 U/ml Lot: 0011502 α(2–3,6) β(1–3) glycopeptides, in a 10 µl reaction for 20 hours at β(1–4) ) of enzyme required to cleave > 95% of the terminal 37°C. The reaction products were analyzed by TLC (1–3 RECOMBINANT Store at –20°C Exp: 2/17 α α-Neu5Ac from 1 nmol Neu5Acα2-3Galβ1- for digestion of substrate. 3GlcNAc 1-3Gal 1-4Glc-AMC, in 1 hour at 37°C in Description: β β Neuraminidase is the common name α(2–3,6) β(1–4) No other glycosidase activities were detected (ND) (1–2) a total reaction volume of 10 µl. for Acetyl-neuraminyl hydrolase (Sialidase). β with the following substrates: α2-3,6,8,9 Neuraminidase A catalyzes the hy- β(1–4) β(1–2) α(1–6) Unit Definition Assay:Two fold dilutions of α2- drolysis of all linear and branched non-reducing α(1–3) β(1–4) β(1–4) -N-Acetylglucosaminidase: β(1–4) 3,6,8,9 Neuraminidase A are incubated with 1 nmol β terminal sialic acid residues from glycoproteins and GlcNAcβ1-4GlcNAcβ1-4GlcNAc-AMC ND (2–6) (1–4) (1–2)AMC-labeled(1–3) substrate and 1X GlycoBuffer 1 in oligosaccharides. The enzyme releases α2-3 and β(1–4) Gal β(1–2)β(1–4)Man βα(1–4)(1–3)GlcNAcβ(1–6) β(1–6)NeuAc α R = any sugarβ β α a 10 µl reaction. The reaction mix is incubated at α2-6 linkages at a slightly higher rate than α2-8 β(1–4) β(1–4) β(1–4) β(1–4) β(1–N) Asn α(2–6) 37°C for 1 hour. Separation of reaction products are β-N-Acetylgalactosaminidase: and α2-9 linkages. β(1–4) β(1–2) α(1–6) β(1–3) β(1–3)β(1–3) β(1–3)or GalNAcβ1-4Galβ1-4Glc-AMC ND visualized via thin layer chromatographyα(1–6) (3). Specificity: α(2–3) α(1–3) α(2–6) α(1–3) β(1–4) β(1–6) Specific Activity: ~316,000 units/mg. >α(2–8) (see other side) >α(2–9) R CERTIFICATE OF ANALYSIS Detailed Specificity: Source: Cloned from Arthrobacter ureafaciens and Molecular Weight: 100,000 daltons. α2-3,6,8,9 α2-3,6,8,9 Neuraminidase A will cleave branched expressed in E. coli (2). sialic acid residues that are linked to an internal resi- Quality Assurance: No contaminating Neuraminidase A due. This oligosaccharide from fetuin is an example Supplied in: 50 mM NaCl, 20 mM Tris-HCl (pH 7.5 @ exoglycosidase or endoglycosidase F1, F2 or of a side-branch sialic acid residue that can efficiently 25°C) and 1 mM EDTA. F3 activity could be detected. No contaminating 1-800-632-7799 be cleaved (1). proteolytic activity could be detected. [email protected] Reagents Supplied with Enzyme: www.neb.com 10X GlycoBuffer 1 α(2–3,6) β(1–4) β(1–2) Quality Controls P0722S 001150217021 (0.5 M Sodium Acetate, pH 5.5 @ 25°C and α Glycosidase Assays: 100 units of α2-3,6,8,9 (1–6) 50 mM CaCl ) 2 Neuraminidase A were incubated with 0.1 mM P0722S 2–3,6) β(1–4) β(1–4) of flourescently-labeled oligosaccharides and α( Unit Definition: One unit is defined as the amount 800 units 20,000 U/ml Lot: 0011502 α(2–3,6) β(1–3) glycopeptides, in a 10 µl reaction for 20 hours at β(1–4) ) of enzyme required to cleave > 95% of the terminal 37°C. The reaction products were analyzed by TLC (1–3 RECOMBINANT Store at –20°C Exp: 2/17 α α-Neu5Ac from 1 nmol Neu5Acα2-3Galβ1- for digestion of substrate. 3GlcNAc 1-3Gal 1-4Glc-AMC, in 1 hour at 37°C in Description: β β Neuraminidase is the common name α(2–3,6) β(1–4) No other glycosidase activities were detected (ND) (1–2) a total reaction volume of 10 µl. for Acetyl-neuraminyl hydrolase (Sialidase). β with the following substrates: α2-3,6,8,9 Neuraminidase A catalyzes the hy- β(1–4) β(1–2) α(1–6) Unit Definition Assay:Two fold dilutions of α2- drolysis of all linear and branched non-reducing α(1–3) β(1–4) β(1–4) -N-Acetylglucosaminidase: β(1–4) 3,6,8,9 Neuraminidase A are incubated with 1 nmol β terminal sialic acid residues from glycoproteins and GlcNAcβ1-4GlcNAcβ1-4GlcNAc-AMC ND (2–6) (1–4) (1–2)AMC-labeled(1–3) substrate and 1X GlycoBuffer 1 in oligosaccharides. The enzyme releases α2-3 and β(1–4) Gal β(1–2)β(1–4)Man βα(1–4)(1–3)GlcNAcβ(1–6) β(1–6)NeuAc α R = any sugarβ β α a 10 µl reaction. The reaction mix is incubated at α2-6 linkages at a slightly higher rate than α2-8 β(1–4) β(1–4) β(1–4) β(1–4) β(1–N) Asn α(2–6) 37°C for 1 hour. Separation of reaction products are β-N-Acetylgalactosaminidase: and α2-9 linkages. β(1–4) β(1–2) α(1–6) β(1–3) β(1–3)β(1–3) β(1–3)or visualized via thin layer chromatography (3). GalNAcβ1-4Galβ1-4Glc-AMC ND Specificity: α(1–6) α(2–3) α(1–3) α(2–6) α(1–3) β(1–4) β(1–6) Specific Activity: ~316,000 units/mg. >α(2–8) (see other side) >α(2–9) R CERTIFICATE OF ANALYSIS α-N-Acetylgalactosaminidase: β-Xylosidase: Reaction Conditions: Optimal incubation times References: GalNAcα1-3(Fucα1-2)Galβ1-4Glc-AMC ND Xylβ1-4Xylβ1-4Xylβ1-4Xyl-AMC ND and enzyme concentrations must be determined 1. Iwamori, M., Ohta, Y., Uchida, Y. and Tsukada, empirically for a particular substrate. Typical Y. (1997) Glycocon. J., 1, 67–73. α-Fucosidase: β-Mannosidase: reaction conditions are as follows: 2. McLeod, E. New England Biolabs, Inc., unpub- Galβ1-4 (Fucα1-3)GlcNAcβ1-3Galβ1-4Glc-AMC ND Manβ1-4Manβ1-4Man-AMC ND 1. Combine 1 µg of glycoprotein or 100 nM of lished results. Fucα1-2Galβ1-4Glc-AMC ND oligosaccharide and H 0 (if necessary) to make Endo F , F , H: 2 3. Wong-Madden, S. T. and Landry, D. (1995) 1 2 a 9 µl total reaction volume. Glycobiology 5, 19–28. β-Galactosidase: Dansylated invertase high mannose. ND Galβ1-3GlcNAcβ1-4Galβ1-4Glc -AMC ND 2. Add 1 µl of 10X GlycoBuffer 1 to make a 10 µl total reaction volume. Galβ1-4GlcNAcβ1-3Galβ1-4Glc -AMC ND Endo F2, F3: Dansylated fibrinogen biantennary. ND 3. Add 1 µl of α2-3,6,8,9 Neuraminidase A. ISO 9001 ISO 14001 ISO 13485 α-Galactosidase: Registered Registered Registered Quality Environmental Medical Devices Galα1-3Galβ1-4Gal-AMC ND Protease Assay: After incubation of 1,000 units 4. Incubate at 37°C for 1 hour. Management Management Gal 1-6Gal 1-6Glc 1-2Fru-AMC ND of 2-3,6,8,9 Neuraminidase A with 0.2 nmol of a α α α α NEW ENGLAND BIOLABS® is a registered trademark of New England standard mixture of proteins in a 20 µl reaction, for Notes on Use: Biolabs, Inc. α-Mannosidase: 20 hours at 37°C, no proteolytic activity could be • Reactions may be scaled-up linearly to Manα1-3Manβ1-4GlcNAc-AMC ND detected by SDS-PAGE. accommodate larger reaction volumes. Manα1-6Manα1-6(Manα1-3)Man-AMC ND • The amount of exoglycosidase enzyme required Physical Purity: Purified to > 95% homogeneity as varies when different substrates are used. Start α-Glucosidase: determined by SDS-PAGE analysis using Coomassie with 1–2 µl for 1 µg of glycoprotein or 100 nM Glcα1-6Glcα1-4Glc-AMC ND Blue detection. of oligosaccharide for one hour in a 10–25 µl reaction. If there is still undigested material, let Heat Inactivation: 75°C for 10 minutes. the reaction go overnight. • Higher concentrations of enzyme as well as longer incubation times may be necessary for Page 2 (P0722) cleavage of branched structures. α-N-Acetylgalactosaminidase: β-Xylosidase: Reaction Conditions: Optimal incubation times References: GalNAcα1-3(Fucα1-2)Galβ1-4Glc-AMC ND Xylβ1-4Xylβ1-4Xylβ1-4Xyl-AMC ND and enzyme concentrations must be determined 1.
Load more

Recommended publications
  • Assessing Mimicry of the Transition State
    View Article Online / Journal Homepage / Table of Contents for this issue PERSPECTIVE www.rsc.org/obc | Organic & Biomolecular Chemistry Glycosidase inhibition: assessing mimicry of the transition state Tracey M. Gloster*a,b and Gideon J. Davies*a Received 5th August 2009, Accepted 30th September 2009 First published as an Advance Article on the web 5th November 2009 DOI: 10.1039/b915870g Glycoside hydrolases, the enzymes responsible for hydrolysis of the glycosidic bond in di-, oligo- and polysaccharides, and glycoconjugates, are ubiquitous in Nature and fundamental to existence. The extreme stability of the glycosidic bond has meant these enzymes have evolved into highly proficient catalysts, with an estimated 1017 fold rate enhancement over the uncatalysed reaction. Such rate enhancements mean that enzymes bind the substrate at the transition state with extraordinary affinity; the dissociation constant for the transition state is predicted to be 10-22 M. Inhibition of glycoside hydrolases has widespread application in the treatment of viral infections, such as influenza and HIV, lysosomal storage disorders, cancer and diabetes. If inhibitors are designed to mimic the transition state, it should be possible to harness some of the transition state affinity, resulting in highly potent and specific drugs. Here we examine a number of glycosidase inhibitors which have been developed over the past half century, either by Nature or synthetically by man. A number of criteria have been proposed to ascertain which of these inhibitors are true transition state mimics, but these features have only be critically investigated in a very few cases. Introduction molecules, lipids or proteins), constitute between 1 and 3% of the genome of most organisms.1 The task facing these enzymes Glycosidases, the enzymes responsible for the breakdown of di-, with respect to maintaining efficient and highly specific catalysis oligo- and polysaccharides, and glyconjugates, are ubiquitous is no mean feat; it has been calculated that there are 1.05 ¥ 1012 through all kingdoms of life.
    [Show full text]
  • Oxidative Stress, a New Hallmark in the Pathophysiology of Lafora Progressive Myoclonus Epilepsy Carlos Romá-Mateo *, Carmen Ag
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Digital.CSIC 1 Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy Carlos Romá-Mateo1,2*, Carmen Aguado3,4*, José Luis García-Giménez1,2,3*, Erwin 3,4 3,5 1,2,3# Knecht , Pascual Sanz , Federico V. Pallardó 1 FIHCUV-INCLIVA. Valencia. Spain 2 Dept. Physiology. School of Medicine and Dentistry. University of Valencia. Valencia. Spain 3 CIBERER. Centro de Investigación Biomédica en Red de Enfermedades Raras. Valencia. Spain. 4 Centro de Investigación Príncipe Felipe. Valencia. Spain. 5 IBV-CSIC. Instituto de Biomedicina de Valencia. Consejo Superior de Investigaciones Científicas. Valencia. Spain. * These authors contributed equally to this work # Corresponding author: Dr. Federico V. Pallardó Dept. Physiology, School of Medicine and Dentistry, University of Valencia. E46010-Valencia, Spain. Fax. +34963864642 [email protected] 2 ABSTRACT Lafora Disease (LD, OMIM 254780, ORPHA501) is a devastating neurodegenerative disorder characterized by the presence of glycogen-like intracellular inclusions called Lafora bodies and caused, in most cases, by mutations in either EPM2A or EPM2B genes, encoding respectively laforin, a phosphatase with dual specificity that is involved in the dephosphorylation of glycogen, and malin, an E3-ubiquitin ligase involved in the polyubiquitination of proteins related with glycogen metabolism. Thus, it has been reported that laforin and malin form a functional complex that acts as a key regulator of glycogen metabolism and that also plays a crucial role in protein homeostasis (proteostasis). In relationship with this last function, it has been shown that cells are more sensitive to ER-stress and show defects in proteasome and autophagy activities in the absence of a functional laforin-malin complex.
    [Show full text]
  • The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue
    The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue JOHN F. TALLMAN, WILLIAM G. JOHNSON, and ROSCOE 0. BRADY From the Developmental and Metabolic Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland 20014, and the Department of Biochemistry, Georgetown University School of Medicine, Washington, D. C. 20007 A B S T R A C T The catabolism of Tay-Sachs ganglioside, date fronm the 19th century and over 599 cases have been N-acetylgalactosaminyl- (N-acetylneuraminosyl) -galac- reported (1). Onset of the disease is in the first 6 months tosylglucosylceramide, has been studied in lysosomal of life and is characterized by apathy, hyperacusis, motor preparations from normal human brain and brain ob- weakness, and appearance of a macular cherry-red spot tained at biopsy from Tay-Sachs patients. Utilizing Tay- in the retina. Seizures and progressive mental deteriora- Sachs ganglioside labeled with '4C in the N-acetylgalac- tion follow with blindness, deafness, and spasticity, lead- tosaminyl portion or 3H in the N-acetylneuraminosyl ing to a state of decerebrate rigidity. These infants usu- portion, the catabolism of Tay-Sachs ganglioside may be ally die by 3 yr of age (2). initiated by either the removal of the molecule of A change in the chemical composition of the brain of N-acetylgalactosamine or N-acetylneuraminic acid. The such patients was first detected by Klenk who showed activity of the N-acetylgalactosamine-cleaving enzyme that there was an increase in the ganglioside content (hexosaminidase) is drastically diminished in such compared with normal human brain tissue (3).
    [Show full text]
  • Summary of Neuraminidase Amino Acid Substitutions Associated with Reduced Inhibition by Neuraminidase Inhibitors
    Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors. Susceptibility assessed by NA inhibition assays Source of Type/subtype Amino acid N2 b (IC50 fold change vs wild type [NAI susceptible virus]) viruses/ References Comments substitutiona numberinga Oseltamivir Zanamivir Peramivir Laninamivir selection withc A(H1N1)pdm09 I117R 117 NI (1) RI (10) ? ?d Sur (1) E119A 119 NI/RI (8-17) RI (58-90) NI/RI (7-12) RI (82) RG (2, 3) E119D 119 RI (25-23) HRI (583-827) HRI (104-286) HRI (702) Clin/Zan; RG (3, 4) E119G 119 NI (1-7) HRI (113-1306) RI/HRI (51-167) HRI (327) RG; Clin/Zan (3, 5, 6) E119V 119 RI (60) HRI (571) RI (25) ? RG (5) Q136K/Q 136 NI (1) RI (20) ? ? Sur (1) Q136K 136 NI (1) HRI (86-749) HRI (143) RI (42-45) Sur; RG; in vitro (2, 7, 8) Q136R was host Q136R 136 NI (1) HRI (200) HRI (234) RI (33) Sur (9) cell selected D151D/E 151 NI (3) RI (19) RI (14) NI (5) Sur (9) D151N/D 151 RI (22) RI (21) NI (3) NI (3) Sur (1) R152K 152 RI(18) NI(4) NI(4) ? RG (3, 6) D199E 198 RI (16) NI (7) ? ? Sur (10) D199G 198 RI (17) NI (6) NI (2) NI (2) Sur; in vitro; RG (2, 5) I223K 222 RI (12–39) NI (5–6) NI (1–4) NI (4) Sur; RG (10-12) Clin/No; I223R 222 RI (13–45) NI/RI (8–12) NI (5) NI (2) (10, 12-15) Clin/Ose/Zan; RG I223V 222 NI (6) NI (2) NI (2) NI (1) RG (2, 5) I223T 222 NI/RI(9-15) NI(3) NI(2) NI(2) Clin/Sur (2) S247N 246 NI (4–8) NI (2–5) NI (1) ? Sur (16) S247G 246 RI (15) NI (1) NI (1) NI (1) Clin/Sur (10) S247R 246 RI (36-37) RI (51-54) RI/HRI (94-115) RI/HRI (90-122) Clin/No (1)
    [Show full text]
  • Letters to Nature
    letters to nature Received 7 July; accepted 21 September 1998. 26. Tronrud, D. E. Conjugate-direction minimization: an improved method for the re®nement of macromolecules. Acta Crystallogr. A 48, 912±916 (1992). 1. Dalbey, R. E., Lively, M. O., Bron, S. & van Dijl, J. M. The chemistry and enzymology of the type 1 27. Wolfe, P. B., Wickner, W. & Goodman, J. M. Sequence of the leader peptidase gene of Escherichia coli signal peptidases. Protein Sci. 6, 1129±1138 (1997). and the orientation of leader peptidase in the bacterial envelope. J. Biol. Chem. 258, 12073±12080 2. Kuo, D. W. et al. Escherichia coli leader peptidase: production of an active form lacking a requirement (1983). for detergent and development of peptide substrates. Arch. Biochem. Biophys. 303, 274±280 (1993). 28. Kraulis, P.G. Molscript: a program to produce both detailed and schematic plots of protein structures. 3. Tschantz, W. R. et al. Characterization of a soluble, catalytically active form of Escherichia coli leader J. Appl. Crystallogr. 24, 946±950 (1991). peptidase: requirement of detergent or phospholipid for optimal activity. Biochemistry 34, 3935±3941 29. Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and (1995). the thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11, 281±296 (1991). 4. Allsop, A. E. et al.inAnti-Infectives, Recent Advances in Chemistry and Structure-Activity Relationships 30. Meritt, E. A. & Bacon, D. J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277, 505± (eds Bently, P. H. & O'Hanlon, P. J.) 61±72 (R. Soc. Chem., Cambridge, 1997).
    [Show full text]
  • Lactose Intolerance and Health: Evidence Report/Technology Assessment, No
    Evidence Report/Technology Assessment Number 192 Lactose Intolerance and Health Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA 290-2007-10064-I Prepared by: Minnesota Evidence-based Practice Center, Minneapolis, MN Investigators Timothy J. Wilt, M.D., M.P.H. Aasma Shaukat, M.D., M.P.H. Tatyana Shamliyan, M.D., M.S. Brent C. Taylor, Ph.D., M.P.H. Roderick MacDonald, M.S. James Tacklind, B.S. Indulis Rutks, B.S. Sarah Jane Schwarzenberg, M.D. Robert L. Kane, M.D. Michael Levitt, M.D. AHRQ Publication No. 10-E004 February 2010 This report is based on research conducted by the Minnesota Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2007-10064-I). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment. This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies.
    [Show full text]
  • Datasheet for Neuraminidase (P0720; Lot 0151305)
    Source: Cloned from Clostridium perfringens (1) Unit Definition Assay: Two fold dilutions of No other glycosidase activities were detected (ND) and overexpressed in E. coli at NEB (2). Neuraminidase are incubated with 1 nmol AMC- with the following substrates: Neuraminidase labeled substrate and 1X G1 Reaction Buffer in a Supplied in: 50 mM NaCl, 20 mM Tris-HCl 10 µl reaction. The reaction mix is incubated at 37°C β-N-Acetyl-glucosaminidase: (pH 7.5 @ 25°C) and 5 mM Na2EDTA. for 5 minutes. Separation of reaction products are GlcNAcβ1-4GlcNAcβ1-4GlcNAc-AMC ND 1-800-632-7799 visualized via thin layer chromatography (3). [email protected] Reagents Supplied with Enzyme: α-Fucosidase: www.neb.com 10X G1 Reaction Buffer Specific Activity: ~200,000 units/mg. Fucα1-2Galβ1-4Glc-AMC Galβ1-4 P0720S 015130515051 (Fucα1-3)GlcNAcβ1-3Galβ1-4Glc-AMC ND Reaction Conditions: Molecular Weight: 43,000 daltons. P0720S 1X G1 Reaction Buffer: β-Galactosidase: 50 mM Sodium Citrate (pH 6.0 @ 25°C). Quality Assurance: No contaminating Galβ1-3GlcNAcβ1-4Galβ1-4Glc-AMC ND 2,000 units 50,000 U/ml Lot: 0151305 Incubate at 37°C. exoglycosidase or proteolytic activity could be RECOMBINANT Store at –20°C Exp: 5/15 detected. α-Galactosidase: Optimal incubation times and enzyme Galα1-3Galβ1-4Galα1-3Gal-AMC ND Description: Neuraminidase is the common name concentrations must be determined empirically for Quality Controls for Acetyl-neuraminyl hydrolase (Sialidase). This a particular substrate. α-Mannosidase: Neuraminidase catalyzes the hydrolysis of α2-3, Glycosidase Assays: 500 units of Neuraminidase were incubated with 0.1 mM of flourescently-labeled Manα1-3Manβ1-4GlcNAc-AMC α2-6 and α2-8 linked N-acetyl-neuraminic acid Unit Definition: One unit is defined as the amount Manα1-6Manα1-6(Manα1-3)Man-AMC ND residues from glycoproteins and oligosaccharides.
    [Show full text]
  • Comparative Genomic Analysis of the Emerging Pathogen
    bioRxiv preprint doi: https://doi.org/10.1101/468462; this version posted November 12, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Comparative genomic analysis of the emerging pathogen Streptococcus 2 pseudopneumoniae: novel insights into virulence determinants and 3 identification of a novel species-specific molecular marker 4 5 Geneviève Garriss1†, Priyanka Nannapaneni1†, Alexandra S. Simões2, Sarah Browall1, Raquel Sá- 6 Leão2, 3, Herman Goossens4, Herminia de Lencastre2, 5, Birgitta Henriques-Normark 1, 6, 7 7 8 9 10 1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 11 Stockholm, Sweden 12 2Laboratory of Molecular Genetics, Instituto de Tecnologia Química e Biológica Antonio Xavier, 13 Universidade Nova de Lisboa, Oeiras, Portugal 14 3Department of Plant Biology, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal. 15 4Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), 16 University of Antwerp, Antwerp Belgium 17 5Laboratory of Microbiology and Infectious Diseases, The Rockefeller University, New York, NY, 18 USA 19 6Public Health Agency Sweden, SE-171 82 Solna, Sweden 20 7Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska University 21 Hospital, Solna, Sweden. 22 23 †These authors contributed equally. 24 25 Corresponding author: Birgitta Henriques-Normark, Professor, MD, Karolinska University hospital 26 and Karolinska Institutet, MTC, Nobels väg 16, SE-171 77 Stockholm, Sweden, 27 Email: [email protected] 28 29 30 bioRxiv preprint doi: https://doi.org/10.1101/468462; this version posted November 12, 2018.
    [Show full text]
  • Experimentally Demonstrated the Intrinsic Instability of the Fluorite-Type Zr Cation Network
    0246110 Rta(i) 1 1,2 l,4 1,6 1,l 2 22 Rta(i) Figure 2. Temperature dependence of Zr-FTfor pure orthorhombic zirconia Figure 3 Temperature dependence of Zr-0 shell in tetragonal zirconia solid solution Our study has experimentally demonstrated the intrinsic instability of the fluorite-type Zr cation network. Coherent scattering beween Conclusions central Zr ion and distant cations is weaker and vibration modes of the Zr-cation network are It is found that, for all of zirconia solid softer in tetragonal zirconia than in monoclmic, solutions studied, the dopant-oxygen distances are orthorhombic, or stabilized cubic zirconia. In si@icantly ddferent from the Zr-0 distances. addition, the outer foux oxygens in the 8-fold The dopant-cation distances, on the other hand, coordinated Zr-0 polyhedron are only loosely are usually very close to the Zr-Zr distance, solutions. A bonded and are subject to very large static and confirming the formation of solid dynamic distortions. This effect is illustrated by general structural picture for zirconia solid the expanded portion of the Fourier transform solutions is one that places the dopant cations shown in Figure 3. randomly on tbe Zr sites in the cation network, but with distorted and sometimes very different Dopant Structure dopant-oxygen polyhedra surrounding these dopants. In the case of Ge4+ doping and Y-Nb We have also successfully performed co-doping, short-rangecation ordering has been EXAFS experiments at the dopant absorption suggested from our EXAFS results. edges for doped zirconia solid solutions. Dopants Based on the above structural information studied include the Ce-,Nb-, and Y-K edges as and other EXAFS results obtained from NSLS, well as Ce-LIn edge.
    [Show full text]
  • Glycoproteomics Understanding Protein Modifications
    Now includes O-Glycoprotease Glycoproteomics UNDERSTANDING PROTEIN MODIFICATIONS OVERVIEW TABLE OF CONTENTS Glycoproteomics Products 3–5 Deglycosylation Enzymes 4 Protein Deglycosylation Mix II New England Biolabs (NEB) offers a selection of endoglycosidases and exoglycosidases for glycobiology research. Many of these reagents are recombinant, and all undergo several 5–10 N-linked Deglycosylation Enzymes quality control assays, enabling us to provide products with lower unit cost, high purity 5 PNGase F and reduced lot-to-lot variation. All of our glycosidases are tested for contaminants. Since 6–7 Rapid™ PNGase F p-nitrophenyl-glycosides are not hydrolyzed by some exoglycosidases, we use only fluores- 7 PNGase A 8 Remove-iT PNGase F cently-labeled oligosaccharides to screen for contaminating glycosidases. 8 Endo S Glycobiology is the study of the structure, function and biology of carbohydrates, also 9 Endo D 9 Endo F2 called glycans, which are widely distributed in nature. It is a small but rapidly growing 10 Endo F3 field in biology, with relevance to biomedicine, biotechnology and basic research. 10 Endo H Proteomics, the systematic study of proteins in biological systems, has expanded the 10 Endo Hf knowledge of protein expression, modification, interaction and function. However, in eukaryotic cells the majority of proteins are post-translationally modified (1). A common 11 O-linked Deglycosylation Enzymes post-translational modification, essential for cell viability, is the attachment of glycans, 11 O-Glycosidase shown in Figure 1. Glycosylation defines the adhesive properties of glycoconjugates and 11 Companion Products it is largely through glycan–protein interactions that cell–cell and cell–pathogen contacts 11 Rapid PNGase F Antibody Standard occur, a fact that accentuates the importance of glycobiology.
    [Show full text]
  • Dissecting Conformational Contributions to Glycosidase Catalysis and Inhibition
    This is a repository copy of Dissecting conformational contributions to glycosidase catalysis and inhibition. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/84289/ Version: Published Version Article: Speciale, Gaetono, Thompson, Andrew James orcid.org/0000-0001-7865-1856, Davies, Gideon John orcid.org/0000-0002-7343-776X et al. (1 more author) (2014) Dissecting conformational contributions to glycosidase catalysis and inhibition. CURRENT OPINION IN STRUCTURAL BIOLOGY. pp. 1-13. ISSN 0959-440X https://doi.org/10.1016/j.sbi.2014.06.003 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Available online at www.sciencedirect.com ScienceDirect Dissecting conformational contributions to glycosidase catalysis and inhibition 1 2 2 Gaetano Speciale , Andrew J Thompson , Gideon J Davies and 1 Spencer J Williams Glycoside hydrolases (GHs) are classified into >100 sequence- as of 2014) [2]. What continues to occupy the attention of based families.
    [Show full text]
  • A Gene (Neu-1) on Chromosome 17 of the Mouse Affects Acid O-Glucosidase and Codes for Neuraminidase
    Genet. Res., Camb. (1918), 38, pp. 47-55 47 With 1 plate and 1 text-figure Printed in Great Britain A gene (Neu-1) on chromosome 17 of the mouse affects acid o-glucosidase and codes for neuraminidase BY JOSEPHINE PETERS,1 DALLAS M. SWALLOW,2 SANDRA J. ANDREWS,1 AND LORRAINE EVANS2 1 MRC Radiobiology Unit, Harwell, Didcot, Oxon, 0X11 ORD, U.K. 2 MRC Human Biochemical Genetics Unit, Galton Laboratory University College London, Wolf son House, 4 Stephenson Way, London NW1 2HE, U.K, (Received 13 November 1980 and in revised form 19 December 1980) SUMMARY An electrophoretically detectable variant of acid a-glucosidase has been found in SM/J mice. This variant is attributable to excess sialylation of the enzyme and is determined by a gene, alpha-glucosidase processing, Aglp, on chromosome 17. In addition, as also reported by Potier, Lu Shun Yan & Womack (1979), SM/J mice are relatively deficient in neuraminidase and it appears that the low level of this enzyme in SM/J is determined by an autosomal codominant gene, neuraminidase-1, Neu-1. Preliminary data indicate that Neu-1 is also on chromosome 17. It seems probable that the several processing genes Apl, Aglp and Map-2 which are all closely linked on chromosome 17 are one and the same, a gene Neu-1 coding for neuraminidase. 1. INTRODUCTION A number of genes have been identified in the mouse, Mus musculus, which determine differences in the degree of sialylation of enzymes which are glyco- proteins. These include alpha-mannosidase processing-1 (Map-1) and alpha- mannosidase processing-2 (Map-2) which influence the sialylation of a-manno- sidase (EC 3.2.1.24) (Dizik & Elliott, 1977, 1978) and acid phosphatase-liver (Apl) which affects acid phosphatase (EC 3.1.3.2) (Lalley & Shows, 1977).
    [Show full text]